AG
ACAD icon

Advisor Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Advisor Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$153K Buy
3,577
+440
+14% +$19.1K ﹤0.01% 2605
2019
Q3 		$113K Buy
3,137
+1,702
+119% +$51.6K ﹤0.01% 2795
2019
Q2 		$38K Sell
1,435
-3,112
-68% -$79.5K ﹤0.01% 3554
2019
Q1 		$122K Buy
4,547
+135
+3% +$3.15K ﹤0.01% 2682
2018
Q4 		$70K Sell
4,412
-555
-11% -$10.8K ﹤0.01% 2941
2018
Q3 		$104K Buy
4,967
+1,254
+34% +$19.7K ﹤0.01% 2722
2018
Q2 		$57K Sell
3,713
-578
-13% -$10.3K ﹤0.01% 2971
2018
Q1 		$96K Sell
4,291
-305
-7% -$8.44K ﹤0.01% 2587
2017
Q4 		$139K Buy
4,596
+1,220
+36% +$39K ﹤0.01% 2303
2017
Q3 		$128K Hold
3,376
– – ﹤0.01% 2198
2017
Q2 		$94K Buy
3,376
+1,460
+76% +$43.5K ﹤0.01% 2357
2017
Q1 		$66K Buy
1,916
+1,768
+1,195% +$62.4K ﹤0.01% 2490
2016
Q4 		$4K Sell
148
-647
-81% -$17.1K ﹤0.01% 3993
2016
Q3 		$26K Buy
795
+71
+10% +$2.41K ﹤0.01% 2979
2016
Q2 		$21K Buy
+724
New +$24.2K ﹤0.01% 3036

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisor Group's ACAD Position: Q4 2019 in Review

Advisor Group increased its Acadia Pharmaceuticals (ACAD) stake by 14% in Q4 2019, buying an estimated $19.1K and bringing the position to 3,577 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #2605.

Advisor Group first reported a position in ACAD in Q2 2016 and has held it in 15 quarters since. 273 funds tracked by Wall St. Rank hold ACAD as of Q4 2019.

  • Advisor Group held 3,577 shares of Acadia Pharmaceuticals worth $153K as of Q4 2019.
  • Advisor Group bought 440 Acadia Pharmaceuticals shares in Q4 2019, an estimated $19.1K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #2605 holding.
  • Advisor Group first reported a position in Acadia Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
  • 273 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.